Skip to content Skip to footer
Subscribe Now

TOP 20

Biopharma M&A Top 20 2024
Top 20 Biopharma M&A of 2024 by Total Deal Value
Top 20 Biopharma M&A of 2024 by Total Deal Value Shots: Dealmaking in 2024 experienced fluctuations due to regulatory challenges and increasing pressure from the Inflation Reduction Act The highest-value deal of the year was Vertex’s acquisition of Alpine Immune Sciences for $4.9B, followed by Gilead’s acquisition of CymaBay for $4.3B and Lilly’s acquisition of…
February 6, 2025
Animal Health Top 20 2024
Top 20 Animal Health Companies of 2024
Shots: The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental care The global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030 PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of…
December 12, 2024
cell & gene therapy Top 20 2024
Top 20 Cell and Gene Therapy Companies of 2024
Shots: Cell and gene therapies provide a promising opportunity to enhance care for unmet healthcare needs. Biopharma companies are actively exploring these therapies across multiple indications to address healthcare gaps in rare and chronic diseases In 2023, the cell and gene therapy market was valued at $18.2B and is projected to grow to $117.46B by…
November 28, 2024
Contract Development and Manufacturing Organizations (CDMO) Top 20 2024
20 Contract Development and Manufacturing Organizations (CDMO) of 2024
Shots: CDMOs are at the forefront of pharmaceutical manufacturing, shaping the industry's growth by meeting the increasing global demand for pharmaceutical products In 2023, the global CDMO market was valued at $224.86B, with projections to reach $465.14B by 2032, demonstrating a CAGR of 8.5% PharmaShots presents a comprehensive report on the 20 Contract Development and…
November 14, 2024
Prescription Drugs Top 20 2024
Top 20 Prescription Drugs of 2024
Shots: Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…
October 31, 2024
Countries in Health Innovation Top 20 2024
Top 20 Countries in Health Innovation in 2024
Top 20 Countries in Health Innovation in 2024 Shots: By leveraging high-quality research, PharmaShots brings a meticulously prepared guide to the Top 20 Countries in Health Innovation Using quantitative and qualitative analysis of several aspects encompassing healthcare innovations, PharmaShots dedicatedly navigated the core focus areas of innovations in healthcare while considering trending practices like the…
October 10, 2024
Generic Pharma Top 20 2024
Top 20 Generic Pharma Companies of 2024
Shots: Known for delivering the same therapeutic benefits as its brand-name counterpart, it won't be an exaggeration to refer to generic drugs as modern-day advocates for health equity In 2022, the global market size of generic drugs was valued at $411.99B and is envisioned to reach $613.34B by 2030 with a CAGR of 5.10%. Sandoz…
September 26, 2024
Monoclonal Antibodies Top 20 2024
Top 20 Monoclonal Antibodies of 2024
Shots: Transforming care with advanced mechanisms of action, monoclonal antibody therapies hold a strong foothold in the healthcare market In 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Keytruda with $25.01B revenue ranks first in our list followed by…
September 12, 2024
Oncology Top 20 2024
Top 20 Oncology Companies of 2024
Shots: With more than 50 percent of ongoing clinical trials, Oncology remains one of the most explored therapy areas in healthcare In 2023, the global oncology market was valued at $222.36B and is envisioned to grow to $521.6B by 2033, registering a CAGR of 8.9% from 2024 to 2033. With $27.6B registered oncology revenue, Merck…
August 29, 2024
R&D Spending Biopharma Top 20 2024
Top 20 R&D Spending Biopharma Companies of 2024
Shots: Research & Development (R&D) plays an instrumental role in paving the foundation for innovative therapeutic options in the healthcare sector The global Top 20 pharmaceutical industry spent $148B in 2022 and grew to $180B in 2023, with Merck & Co., had the highest R&D expenditure of $30.53B, followed by Roche ($15.73) and Johnson &…
August 22, 2024
Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]